Equity · Healthcare
CSTL
NASDAQCastle Biosciences (CSTL)
The line runs $24 on 27 July through $33 on 14 October, on a scale from $20 to $40. Days the market did not trade hold the previous close, flat.
as of Oct 14, 2026
Castle Biosciences (CSTL) insider trades
In the 90 days to 24 Oct 2026, Castle Biosciences insiders reported 27 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 15 Jun 2026, show no open-market purchase.
Showing the 12 most recent of 27 open-market trades in this window. The figures above count all of them.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Castle Biosciences (CSTL) reported financials
SEC EDGARCastle Biosciences reported revenue of $344.2M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$24.2M.
Castle Biosciences (CSTL) earnings
Castle Biosciences last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.07; no next date is announced in SEC filings yet.
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
Castle Biosciences (CSTL) institutional holders (13F)
SEC EDGAR9 of the 45 institutional funds we track reported a Castle Biosciences position for the quarter ended 30 Jun 2026 — a combined $40.6M; the latest of those filings landed 02 Sep 2026.
Castle Biosciences (CSTL) fails-to-deliver
SECOn 18 Sep 2026, 125 shares of Castle Biosciences failed to deliver (about $5K).
Congressional trades in Castle Biosciences (CSTL)
House disclosuresThe most recent congressional trade disclosed in Castle Biosciences is a sale by Josh Gottheimer (house, NJ), dated 15 Mar 2022.
Castle Biosciences (CSTL): frequently asked questions
Have Castle Biosciences insiders bought or sold shares recently?
In the 90 days to 24 Oct 2026, Castle Biosciences insiders reported 27 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 15 Jun 2026, show no open-market purchase. A further 12 filings were grants, awards, gifts or exercises rather than open-market trades.
How many institutions hold Castle Biosciences?
9 of the 45 institutional funds we track reported a Castle Biosciences position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.
Has Castle Biosciences had fails-to-deliver recently?
Yes. The most recent SEC fails-to-deliver record for Castle Biosciences is dated 18 Sep 2026, when 125 shares failed to deliver.
When did Castle Biosciences last report earnings?
Castle Biosciences last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.07; no next date is announced in SEC filings yet.
What exchange is Castle Biosciences listed on?
Castle Biosciences trades on NASDAQ under the ticker CSTL.
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
Sources
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
- SEC EDGARSEC EDGAR 13F filings
- SECSEC fails-to-deliver (CNS) data
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARValuation computed from SEC EDGAR filings